1. Dose of inhaled budesonide required to produce clinical suppression of plasma cortisol;Gordon, A.C.H.; McDonald, C.F.; Thomson, S.A.; Frame, M.H.; Pottage, A.; Crompton, G.K.;EurJ RespirDis,1987
2. Assessment of the efficacy and tolerance of a benzodiazepine antagonist (Ro 15-1788);Rouiller, M.; Forster, A.; Gemperle, M.;Ann Fr Anesth Reanim,1987
3. Early clinical experience in reversing benzodiazepine sedation with flumazenil after short procedures;Geller, E.; Niv, D.; Nevo, Y.; Leykin, Y.; Sorkin, P.; Rudick, V.;Resuscitation,1988
4. The use of flumazenil in the treatment of 34 intoxicated patients;Geller, E.; Niv, D.; Weinbrum, A.; Silbiger, A.; Halpern, P.; Sorkin, P.;Resuscitation,1988
5. Clinical and hemodynamic effects of a specific benzodiazepine antagonist (Ro 15-1788) after open heart surgery;Louis, M.; Forster, A.; Suter, P.M.; Gemperle, M.;Anesthesiology,1984